The EPS beat and cost reduction are positive, but the stock's movement will hinge on clinical catalysts—specifically the amended VERSATILE-003 protocol and any FDA feedback on accelerated approval. Monitor the 8:00 am ET investor webcast for updates on trial enrollment restart and regulatory interactions. The $21.7M cash position provides runway into mid-2027 at current burn rate, but dilution risk remains high given the pre-revenue stage.
Price Chart
Executive Summary
PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, driven by lower R&D and G&A expenses. The EPS of -$0.13 beat the consensus estimate of -$0.14 by 7.1%, but the company remains a pre-revenue clinical-stage biotech with no approved products and a cash runway of $21.7M. The key catalyst is the amended VERSATILE-003 Phase 3 trial protocol incorporating PFS as an interim endpoint, which could enable an accelerated approval pathway for PDS0101 in head and neck cancer.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $7.3M ($0.13/share) vs $8.5M ($0.21/share) in Q1 2025
- EPS of -$0.13 beat consensus estimate of -$0.14 by 7.1%
- Cash balance of $21.7M as of March 31, 2026, down from $26.7M at year-end 2025
- Amended VERSATILE-003 Phase 3 trial to include PFS as interim primary endpoint, potentially enabling accelerated approval for PDS0101
- Positive mCRC data published in JCO: 77.8% ORR at 6 months and ~85% 24-month survival rate with PDS01ADC combination
- R&D expenses decreased to $3.5M from $5.8M YoY due to lower clinical and manufacturing costs
- Accumulated deficit of $224M; total stockholders' equity of $3.9M
Financial Impact
Q1 2026 net loss improved by $1.2M YoY; cash burn of ~$5M in the quarter; no revenue generated
Risk Factors
- Pre-revenue biotech with no approved products; entirely dependent on clinical trial success
- Cash burn of ~$5M/quarter; $21.7M cash provides limited runway without additional financing
- VERSATILE-003 trial amendment may face FDA pushback on accelerated approval pathway
- High dilution risk: weighted average shares outstanding increased 37% YoY to 55.5M
- Accumulated deficit of $224M with no near-term revenue prospects
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293836 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7380 (−146.00%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7380 (+253.28%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7380 (−216.47%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7380 (−187.16%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7380 (−3.14%) |
Jun 26, 2026 13w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7380 (−17.92%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7380 (+23.13%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7380 (−27.65%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7380 (−36.38%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7380 (−44.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access